IFN-γ can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen

Journal of Immunology

Volumn 165, Issue 10, 2000, Pages 5502-5508

  Beatty, G L ^a   Paterson, Y ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; LYMPHOCYTIC INFILTRATION; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0034669980     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.10.5502     Document Type: Article

References (42)

1. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro
2. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
3. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen
4. Immunosuppression and transforming growth factor-β in glioblastoma: Preferential production of transforming growth factor-β2
5. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: Identification of transforming growth factor-β as a suppressive factor
6. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein
7. Overexpression of Bcl-2 enhances metastatic potential of human bladder cancer cells
8. Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model
9. Membrane-bound Fas (Apo-1/CD95) ligand on leukemic cells: A mechanism of tumor immune escape in leukemia patients
10. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
11. Multiple roles of interferon-γ in the mediation of interleukin 12-induced tumor regression
12. Recombinant IL-12 administration induces tumor regression in association with IFN-γ production
13. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10
14. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo
15. Down-regulation of transforming growth factor-β and interleukin-10 secretion from malignant glioma cells by cytokines and anticancer drugs
16. Interferon-γ reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production
17. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors
18. Tumor cell responses to IFN-γ affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
19. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product
20. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with note on carcinogen structure
21. Modification of vectors pEF-BOS, pcDNA-1, pcDNA-3 result in improved convenience and expression
22. Improved retroviral vectors for gene transfer and expression
23. Intracellular murine IFN-γ mediates virus resistance, expression of oligoadenylate synthetase, and activation of STAT transcription factors
24. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
25. Structural domains of endogenous murine leukemia gp70s containing specific antigenic determinants by monoclonal antibodies
26. A rapid technique for isolation of viable tumor cells from solid tumors: Use of the tumor cells for induction and measurement of cell-mediated cytotoxic responses
27. Moloney murine leukemia virus envelope protein subunits, gp70 and pr15e, form a stable disulfide-linked complex
28. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ
29. Tumor-specific immune response: Current in vitro analyses may not reflect the in vivo immune status
30. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
31. Immunogenic (tum-) variants of mouse tumor P815: Cloning of the gene of tum-antigen P19A and identification of the tum-mutation
32. The gene coding for a major tumor rejection antigen to tumor P815 is identical to the normal gene of syngeneic DBA/2 mice
33. Absence of serum prostate-specific antigen and loss of tissue immunoreactive prostatic markers in advanced prostatic adenocarcinoma after hormonal therapy: A report of two cases
34. The effects of interferon on the expression of human papillomavirus oncogenes
35. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
36. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
37. Prognostic value of intratumoral interferon γ messenger RNA expression in invasive cervical carcinomas
38. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells: Comparison with anti-proliferative activity by rIL1-β, rTNF-α, rIFN-γ, rIL4 and their combinations
39. Distinct role of antigen-specific T helper type (Th1) and Th2 cells in tumor eradication in vivo
40. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor
41. Recombinant human interferon γ: Adverse effects in high-risk stage I and II cutaneous malignant melanoma
42. Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-β and recombinant interferon-γ